795 research outputs found

    Adversarial contract design for private data commercialization

    Get PDF
    The proliferation of data collection and machine learning techniques has created an opportunity for commercialization of private data by data aggregators. In this paper, we study this data monetization problem using a contract-theoretic approach. Our proposed adversarial contract design framework accounts for the heterogeneity in honest buyers' demands for data, as well as the presence of adversarial buyers who may purchase data to compromise its privacy. We propose the notion of Price of Adversary (PoAdv) to quantify the effects of adversarial users on the data seller's revenue, and provide bounds on the PoAdv for various classes of adversary utility. We also provide a fast approximate technique to compute contracts in the presence of adversaries

    A Peer to Peer Protocol for Online Dispute Resolution over Storage Consumption

    Full text link
    In bilateral accounting of resource consumption both the consumer and provider independently measure the amount of resources consumed by the consumer. The problem here is that potential disparities between the provider's and consumer's accountings, might lead to conflicts between the two parties that need to be resolved. We argue that with the proper mechanisms available, most of these conflicts can be solved online, as opposite to in court resolution; the design of such mechanisms is still a research topic; to help cover the gap, in this paper we propose a peer--to--peer protocol for online dispute resolution over storage consumption. The protocol is peer--to--peer and takes into consideration the possible causes (e.g, transmission delays, unsynchronized metric collectors, etc.) of the disparity between the provider's and consumer's accountings to make, if possible, the two results converge.Comment: 12 pages, 7 figure

    Implementation of Smart Contracts Using Hybrid Architectures with On- and Off-Blockchain Components

    Full text link
    Recently, decentralised (on-blockchain) platforms have emerged to complement centralised (off-blockchain) platforms for the implementation of automated, digital (smart) contracts. However, neither alternative can individually satisfy the requirements of a large class of applications. On-blockchain platforms suffer from scalability, performance, transaction costs and other limitations. Off-blockchain platforms are afflicted by drawbacks due to their dependence on single trusted third parties. We argue that in several application areas, hybrid platforms composed from the integration of on- and off-blockchain platforms are more able to support smart contracts that deliver the desired quality of service (QoS). Hybrid architectures are largely unexplored. To help cover the gap, in this paper we discuss the implementation of smart contracts on hybrid architectures. As a proof of concept, we show how a smart contract can be split and executed partially on an off-blockchain contract compliance checker and partially on the Rinkeby Ethereum network. To test the solution, we expose it to sequences of contractual operations generated mechanically by a contract validator tool.Comment: 12 pages, 7 figure

    Metal content determination in biodiesel samples by microwave mineralization and ICP-AES

    Get PDF
    El trabajo comprende la puesta a punto de un método de digestión, mediante calentamiento de microondas, de muestras de biodiesel obtenidas mediante catálisis homogénea de aceites vegetales, para la determinación de 20 elementos mediante ICP-AES

    R2 prime (R2') magnetic resonance imaging for post-myocardial infarction intramyocardial haemorrhage quantification.

    Get PDF
    To assess whether R2* is more accurate than T2* for the detection of intramyocardial haemorrhage (IMH) and to evaluate whether T2' (or R2') is less affected by oedema than T2* (R2*), and thus more suitable for the accurate identification of post-myocardial infarction (MI) IMH. Reperfused anterior MI was performed in 20 pigs, which were sacrificed at 120 min, 24 h, 4 days, and 7 days. At each time point, cardiac magnetic resonance (CMR) T2- and T2*-mapping scans were recorded, and myocardial tissue samples were collected to quantify IMH and myocardial water content. After normalization by the number of red blood cells in remote tissue, histological IMH increased 5.2-fold, 10.7-fold, and 4.1-fold at Days 1, 4, and 7, respectively. The presence of IMH was correlated more strongly with R2* (r = 0.69; P = 0.013) than with T2* (r = -0.50; P = 0.085). The correlation with IMH was even stronger for R2' (r = 0.72; P = 0.008). For myocardial oedema, the correlation was stronger for R2* (r = -0.63; P = 0.029) than for R2' (r = -0.50; P = 0.100). Multivariate linear regressions confirmed that R2* values were significantly explained by both IMH and oedema, whereas R2' values were mostly explained by histological IMH (P = 0.024) and were little influenced by myocardial oedema (P = 0.262). Using CMR mapping with histological validation in a pig model of reperfused MI, R2'more accurately detected IMH and was less influenced by oedema than R2* (and T2*). Further studies are needed to elucidate whether R2' is also better suited for the characterization of post-MI IMH in the clinical setting.This study was partially supported by a competitive grant from the Carlos III Institute of Health-Fondo de Investigacion Sanitaria and the European Regional Development Fund (ERDF/FEDER) (PI16/02110), the Spanish Ministry of Science, Innovation and Universities (MICIU), ERDF/FEDER SAF2013-49663-EXP, by the Comunidad de Madrid (S2017/BMD-3867 RENIM-CM) and cofunded with European structural and investment funds. This study forms part of a Master Research Agreement between the CNIC and Philips Healthcare. This research program is part of an institutional agreement between FIIS Fundacion Jimenez Diaz and the CNIC. The CNIC is supported by the Ministry of Science, Innovation and Universities MICIU the Instituto de Salud Carlos III (ISCiii), and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (award SEV-2015-0505). X.R. has received support from the DYSEC-CNIC CARDIOJOVEN fellowship program. R.F.-J. is a recipient of funding from the European Union Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie (Agreement No. 707642).S

    Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Immunohistochemistry (IHC) with mutation-specific antibodies may be an ancillary method of detecting EGFR mutations in lung cancer patients.</p> <p>Methods</p> <p>EGFR mutation status was analyzed by DNA assays, and compared with IHC results in five non-small-cell lung cancer (NSCLC) cell lines and tumor samples from 78 stage IV NSCLC patients.</p> <p>Results</p> <p>IHC correctly identified del 19 in the H1650 and PC9 cell lines, L858R in H1975, and wild-type EGFR in H460 and A549, as well as wild-type EGFR in tumor samples from 22 patients. IHC with the mAb against EGFR with del 19 was highly positive for the protein in all 17 patients with a 15-bp (ELREA) deletion in exon 19, whereas in patients with other deletions, IHC was weakly positive in 3 cases and negative in 9 cases. IHC with the mAb against the L858R mutation showed high positivity for the protein in 25/27 (93%) patients with exon 21 EGFR mutations (all with L858R) but did not identify the L861Q mutation in the remaining two patients.</p> <p>Conclusions</p> <p>IHC with mutation-specific mAbs against EGFR is a promising method for detecting EGFR mutations in NSCLC patients. However these mAbs should be validated with additional studies to clarify their possible role in routine clinical practice for screening EGFR mutations in NSCLC patients.</p

    Regulation of the Intestinal Extra-Adrenal Steroidogenic Pathway Component LRH-1 by Glucocorticoids in Ulcerative Colitis

    Get PDF
    Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) and can be treated with glucocorticoids (GC), although some patients are unresponsive to this therapy. The transcription factor LRH-1/NR5A2 is critical to intestinal cortisol production (intestinal steroidogenesis), being reduced in UC patients. However, the relationship between LRH-1 expression and distribution with altered corticosteroid responses is unknown. To address this, we categorized UC patients by their steroid response. Here, we found that steroid-dependent and refractory patients presented reduced glucocorticoid receptor (GR)-mediated intestinal steroidogenesis compared to healthy individuals and responder patients, possibly related to increased colonic mucosa GR isoform beta (GR beta) content and cytoplasmic LRH-1 levels in epithelial and lamina propria cells. Interestingly, an intestinal epithelium-specific GR-induced knockout (GR(iKO)) dextran sodium sulfate (DSS)-colitis mice model presented decreased epithelial LRH-1 expression, whilst it increased in the lamina propria compared to DSS-treated control mice. Mechanistically, GR directly induced NR5A2 gene expression in CCD841CoN cells and human colonic organoids. Furthermore, GR bound to two glucocorticoid-response elements within the NR5A2 promoter in dexamethasone-stimulated CCD841CoN cells. We conclude that GR contributes to intestinal steroidogenesis by inducing LRH-1 in epithelial cells, suggesting LRH-1 as a potential marker for glucocorticoid-impaired response in UC. However, further studies with a larger patient cohort will be necessary to confirm role of LRH-1 as a therapeutic biomarker
    corecore